Veronique D/iStock Editorial via Getty Images Following the Sandoz spin-off, Novartis (NYSE:NVS) (OTCPK:NVSEF) is now a pure player in innovative medicines, and we are not surprised to see a sharp margin increase. Here at the Lab, after a neutral rating recommendation held for years, we upgraded the company to a buy in April 2024. It was a good call, and Novartis' stock price is currently up by 14.96%, including the dividend payment (Fig 1). Our buy rating was backed by:  Including Q2 2024, the company  ...